Michael Hostetler

Wilson Sonsini Goodrich & Rosati - UNITED STATES


Michael Hostetler's competencies

Practice AreaJurisdictionRankAgg. Deals ValueClients DimensionN. of TransactionsLast Quarter
IP&ITUNITED STATES88591033543
Practice AreaJurisdictionRankAgg. Deals ValueClients DimensionN. of TransactionsLast Quarter
Showing 1 to 1 of 1 entries

Client Reviews

The Client Reviews provides a qualitative rating based on Partners' Clients feedback assessment


Communication Skills

0255075100Below expectationMeet expectationExceed expectation0

Technical skills

0255075100Below expectationMeet expectationExceed expectation0

Efficiency

0255075100Below expectationMeet expectationExceed expectation0


Effectiveness

0255075100Below expectationMeet expectationExceed expectation0



Perceived Added Value

0255075100

Ranking 2022: Michael Hostetler - Wilson Sonsini Goodrich & Rosati

Practice AreaAgg. Deals ValueClients DimensionN. of TransactionsTier
IP&IT607531746
Practice AreaAgg. Deals ValueClients DimensionN. of TransactionsTier
Showing 1 to 1 of 1 entries

Ranking 2021: Michael Hostetler - Wilson Sonsini Goodrich & Rosati

Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier
Corporate M&A45251
Equity Capital Markets75251
Finance85251
IP&IT15254320
Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier

Ranking 2020: Michael Hostetler - Wilson Sonsini Goodrich & Rosati

Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier
IP&IT40007632
Practice Area Agg. Deals Value Clients Dimension N. of Transactions Tier

Significant Clients

The chart shows a balanced list of the Michael Hostetler's client portfolio - based on PBV Monitor's Analyzed Transactions during last Twelve Mounths
Novo Holdings A/SMBX Biosciences Inc.Candid TherapeuticsAvidity BiosciencesVivace Therapeutics, Inc.Vida VenturesVenrockSR OneSeaport TherapeuticsReneo PharmaceuticalsRadionetics OncologyOpus GeneticsNorwest Venture PartnersJanux TherapeuticsInSilico MedicineHaya Therapeutics SAGoldman Sachs AlternativesGeneral AtlanticForte Biosciences, IncEnlaza TherapeuticsDren BioDelos CapitalCrinetics PharmaceuticalsBoundless BioAutobahn Therapeutics858 Therapeutics05K10KRevenue (ML. Euro)

Team

The chart shows a balanced list of counselor working with Michael Hostetler - based on PBV Monitor's analyzed transactions during last Twelve Mounths
Valentin ZunicUale TaotafaMinyoung ShinLaurie McNamaraDan KoeppenYingchun NiStephen HeifetzKassandra CastilloHee Min NohSarah WalkerNorm HovijitraNima ZargariMiranda BivenKarl KobyleckiIngo HardtFeng TianDeborah SmithBrandon ShawYing ChenWendy DevineVictoria ChengTyler KivleyTrevor DorneShuobo BoboilaSean ReedScott McCallRichard WangNguyen Pham Myra SutantoShenMirunaPredescuMatt WheelerLongle MaLaurenHodnettLance BradyKimberleyBiagioliKevin TylockKenneth ClarkJoshuaGruenspechtJordin WilcherJonathanDaveyJohn MaoJacob MoralesDerrick D.RoweCharles TaitGravesBrendanCoffmanBrandon KingBraden E.AndersonBenjaminCappsAnne Seymour09001.8KAgg. deal value (ML. Euro)

Co-Counsel

The Chart shows a balanced list of Michael Hostetler's Co-Counsel Law Firm - based on PBV Monitor's analyzed transactions during last Twelve Mounths
Cooley LLPLatham & WatkinsSmith, Anderson, Blount, Dorsett, Mitchell & JerniganJones DayVISCHER AGMorrison & FoersterGoodwin Procter0397.5795Agg. deal value (ML. Euro)

Counterparts

The Chart shows a balanced list of Michael Hostetler's other Firms involved - based on PBV Monitor's analyzed transactions during last Twelve Mounths

Peer Reviews

The Peer Reviews provides a qualitative rating based on Counterparts / Referees' feedback assessment


0%20%40%60%80%100%Communication SkillsTechnical skillsEfficiencyEffectivenessPerceived Added Value

Recent experiences

Vivace Therapeutics' $35 Million Series D Financing Round3/19/2025
Verdiva Bio’s $410 Million Series A Financing Round1/29/2025
Insilico's License Agreement with Menarini Group1/29/2025
Verdiva Bio’s $410 Million Series A Financing Round1/29/2025
Insilico's License Agreement with Menarini Group1/29/2025
Candid Therapeutics' Agreement with WuXi Biologics1/27/2025
SiteOne Therapeutics’ $100 Million Series C Financing Round12/24/2024